NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). NovoCure's Average Total Inventories for the three months ended in Mar. 2023 was $30.5 Mil. NovoCure's Cost of Goods Sold for the three months ended in Mar. 2023 was $29.6 Mil. Hence, NovoCure's Days Inventory for the three months ended in Mar. 2023 was 94.13.
The historical rank and industry rank for NovoCure's Days Inventory or its related term are showing as below:
During the past 10 years, NovoCure's highest Days Inventory was 156.13. The lowest was 82.37. And the median was 97.77.
NovoCure's Days Inventory increased from Mar. 2022 (88.05) to Mar. 2023 (94.13). It might indicate that NovoCure's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year. NovoCure's Inventory Turnover for the three months ended in Mar. 2023 was 0.97.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NovoCure's Inventory-to-Revenue for the three months ended in Mar. 2023 was 0.25.
The historical data trend for NovoCure's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NovoCure's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Days Inventory distribution charts can be found below:
* The bar in red indicates where NovoCure's Days Inventory falls in comparison to its industry or sector. The grey bar indicates the Days Inventory's extreme value range as defined by GuruFocus.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
NovoCure's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as
Days Inventory (A: Dec. 2022 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2021 ) | + | Total Inventories (A: Dec. 2022 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2022 ) | * | Days in Period |
= | ( (24.427 | + | 29.376) | / | 2 ) | / | 114.867 | * | 365 |
= | 26.9015 | / | 114.867 | * | 365 | ||||
= | 85.48 |
NovoCure's Days Inventory for the quarter that ended in Mar. 2023 is calculated as:
Days Inventory (Q: Mar. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Dec. 2022 ) | + | Total Inventories (Q: Mar. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Mar. 2023 ) | * | Days in Period |
= | ( (29.376 | + | 31.723) | / | 2 ) | / | 29.614 | * | 365 / 4 |
= | 30.5495 | / | 29.614 | * | 365 / 4 | ||||
= | 94.13 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (NAS:NVCR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NovoCure's Inventory Turnover for the three months ended in Mar. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 29.614 | / | 30.5495 | |
= | 0.97 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NovoCure's Inventory to Revenue for the three months ended in Mar. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 30.5495 | / | 122.182 | |
= | 0.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of NovoCure's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Arye Barak Ben | officer: General Counsel | TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905 |
William Patrick Burke | officer: Chief Human Resources Officer | 195 COMMERCE WAY, PORTSMOUTH NH 03801 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Ashley Cordova | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
Frank X Leonard | officer: Chief Development Officer | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
Uri Weinberg | officer: Chief Science Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Ely Benaim | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Pritesh Shah | officer: Chief Commercial Officer | C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Sherilyn S Mccoy | director | JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
David Hung | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Martin J. Madden | director | C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043 |
Steve Futrell | 10 percent owner | 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017 |
Frances Janis | 10 percent owner | 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017 |
Michael D Granoff | 10 percent owner | 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By Business Wire 10-20-2022
By Business Wire 01-05-2023
By Business Wire 06-03-2022
By Business Wire 06-21-2022
By Business Wire 01-09-2023
Other Sources
By Zacks 2023-01-24
By Yahoo Finance 2022-11-11
By Yahoo Finance 2022-10-29
By Yahoo Finance 2023-01-09
By Yahoo Finance 2023-01-19
By Yahoo Finance 2023-01-05
By Yahoo Finance 2023-01-05
By Yahoo Finance 2023-01-05
By Yahoo Finance 2022-10-27
By Yahoo Finance 2023-01-19
By Yahoo Finance 2023-01-19
By Yahoo Finance 2023-01-17
By Seekingalpha 2023-01-09
By Yahoo Finance 2022-11-08
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.